Safety and immunogenicity of the adjunct therapeutic vaccine ID93+ GLA-SE in adult who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Your email address will not be published. Required fields are marked *

Name  *

Email  *

Website

Add Comment *

Save my name, email, and website in this browser for the next time I comment.

Subscribe to our email updates as well.

Post Comment